{
    "clinical_study": {
        "@rank": "62199", 
        "arm_group": [
            {
                "arm_group_label": "ARC-520", 
                "arm_group_type": "Experimental", 
                "description": "Single dose, intravenous administration of ARC-520"
            }, 
            {
                "arm_group_label": "Placebo Comparator, Normal Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single dose, intravenous administration of Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether ARC-520 in combination with entecavir is\n      effective in the treatment of patients with Chronic Hepatitis B Virus (HBV) Infection."
        }, 
        "brief_title": "Study of ARC-520 in Patients With Chronic Hepatitis B Virus", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis B, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Treatment with ARC-520 for injection is expected to reduce all HBV proteins and replicative\n      intermediates via RNA interference. The magnitude of the reduction and duration of effect\n      will depend on the dose. Since to date ARC-520 has not been administered to patients with\n      chronic HBV infection, the effective therapeutic dose in patients with chronic HBV infection\n      is unknown. This study is designed to assess the antiviral activity of ARC-520, especially\n      it's effect on HBsAg, in patients with chronic HBV infection at different dose levels."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Have a diagnosis of HBeAg negative, immune active, chronic HBV infection and all of\n             the following:\n\n               1. History of being HBsAg positive at 2 time points > 6 months apart\n\n               2. HBsAg titer > 1,000 IU/mL determined at screening\n\n               3. HBeAg negative at screening\n\n               4. HBV DNA < 200 IU/mL at screening\n\n          -  Patients with > 6 months of continuous, 0.5 mg/day oral entecavir, and a willingness\n             to continue taking entecavir throughout the study.\n\n        Key Exclusion Criteria:\n\n          -  Female patients that have a positive pregnancy test or are lactating.\n\n          -  Acute signs of hepatitis/other infection (eg, moderate fever, jaundice, nausea,\n             vomiting, and abdominal pain) evident within 4 weeks of screening and/or at the\n             screening examination.\n\n          -  Hepatic transaminases (ALT or AST) > 100 IU/mL at screening.\n\n          -  Patients with antiviral therapy other than entecavir within 3 months of screening or\n             prior treatment with interferon or a toll receptor agonist in the last 5 years.\n\n          -  Use within the last 6 months or an anticipated requirement for anticoagulants,\n             corticosteroids, immunomodulators, or immunosuppressants.\n\n          -  Has any history of autoimmune disease especially autoimmune hepatitis.\n\n          -  Has human immunodeficiency virus (HIV) infection, as shown by the presence of\n             anti-HIV antibody (sero-positive).\n\n          -  Is sero-positive for HCV, and/or a history of delta virus hepatitis.\n\n          -  Has a history of allergy to bee venom or history of hypersensitivity reaction\n             requiring an emergency visit to a physician or hospital and/or requirement for\n             treatment with steroids and/or epinephrine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02065336", 
            "org_study_id": "Heparc-2001"
        }, 
        "intervention": [
            {
                "arm_group_label": "ARC-520", 
                "intervention_name": "ARC-520", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Comparator, Normal Saline", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "HBV", 
            "Hepatitis"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "contact": {
                    "email": "rchwu@hkucc.hku.hk", 
                    "last_name": "Ringo Wu", 
                    "phone": "+852 2255-3579"
                }, 
                "facility": {
                    "address": {
                        "city": "Pokfulam", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Queen Mary Hospital"
                }, 
                "investigator": {
                    "last_name": "Man-Fung Yuen, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "angelchim@cuhk.edu.hk", 
                    "last_name": "Angel Chim", 
                    "phone": "+852 2632-3759"
                }, 
                "facility": {
                    "address": {
                        "city": "Shatin", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Prince of Wales Hospital"
                }, 
                "investigator": {
                    "last_name": "Henry Chan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Hong Kong"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After a Single Intravenous Dose of ARC-520 in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection", 
        "overall_contact": {
            "email": "Winnie.Leung@iconplc.com", 
            "last_name": "Winnie Leung", 
            "phone": "+ 852 9646-3894"
        }, 
        "overall_contact_backup": {
            "email": "dmartin@arrowres.com", 
            "last_name": "Diamond Martin", 
            "phone": "+1 626 696 4704"
        }, 
        "overall_official": {
            "affiliation": "Arrowhead Research Corporation", 
            "last_name": "Bruce Given, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Hong Kong: Department of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Depth and duration of HBsAg reduction as a measure of efficacy", 
            "safety_issue": "No", 
            "time_frame": "Through Day 85"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02065336"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Arrowhead Research Corporation", 
        "sponsors": {
            "collaborator": {
                "agency": "ICON Clinical Research", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Arrowhead Research Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}